ClinicalTrials.gg
Not yet recruitingNCT07679841COLOMBEUpdated Sep 30, 2026

Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients

A Phase 1/2 interventional study of Imiquimod 5% cream and Nivolumab in Vulvar Squamous Cell Carcinoma, sponsored by Centre Leon Berard. Not yet recruiting at 11 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Centre Leon Berard · Phase 1/2, Interventional, and Treatment

How we know · 4 judgments

Updated Sep 30, 20268 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

COLOMBE is a multicenter, single arm, phase 1/2 trial designed to evaluate the safety and efficacy of imiquimod cream with IV low dose nivolumab in primary resectable vulvar squamous cell carcinoma patients prior to surgery, leveraging the preoperative "window of opportunity" period, an unavoidable interval due to surgical scheduling.

02

Conditions studied

  • Vulvar Squamous Cell Carcinoma

Keywords

  • vulvar squamous cell carcinoma
  • nivolumab
  • imiquimod
03

In context

Lead sponsor

Centre Leon Berard is the lead sponsor of 211 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

I1. Female patient ≥ 18 years of age on day of signing .

I2. confirmed primary VSCC, with all of the following characteristics:

  • At least 1 lesion that can be measured in at least 1 dimension with ≥ 10 mm in largest diameter
  • Clinically stage FIGO I-III (2021 FIGO staging)
  • Eligible for primary tumour surgery
  • Surgical complexity due to either bulky tumors > 4 cm OR multifocal tumor (defined as the presence of two or more foci of cancer on the vulva), the largest lesion must be ≥ 10 mm and all lesions ≥ 10 mm are designated as "target" lesion(s) for all subsequent tumor evaluations OR any tumor for which a surgical excision would have anatomical or functional consequences deemed significant by the treating surgeon

I3. Availability of a representative formalin-fixed paraffin-embedded (FFPE) sample of the primary tumor tissue () with an associated pathology report. This tumor sample must meet the following quality/quantity control criteria: ≥30 % of tumor cells and a tumor surface area ≥ 5mm2

I4. (ECOG) Performance Status (PS) ≤ 2

I5. Patients with adequate organ function:

  • (ANC) ≥ 1 10\^9/L
  • ≥ 100 10\^9/L (without transfusion for platelets within 7 days)
  • ≥ 9 g/dL
  • according to ≥ 30 mL/min
  • Serum total ≤ 1.5 x (except for patients with Gilbert disease for whom a total serum bilirubin ≤ 3 x ULN is acceptable)
  • and ALT ≤ 3 x ULN

I6. Women of (WOCBP) must have a negative serum pregnancy test within 7 days prior to C1D1 and must agree to use effective forms of from the time of the negative pregnancy test up to 5 months after the last dose of nivolumab.

I7. Patient should understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.

I8. Patients must be covered by a medical insurance.

Exclusion criteria

Exclusion Criteria:

E1. Patients participating in another clinical trial with therapeutic intent.

E2. Patients previously treated with any anti-cancer treatment including , anti-PDL1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor (e.g., CTLA-4, OX 40, CD37).

E3. Patients not respecting the minimal or receiving or anticipation of need during the study of the following medications/procedure:

  • Major surgery: 2 weeks
  • : 4 weeks
  • Systemic (in dosing exceeding 10 mg daily of prednisone or equivalent) or any other form of therapy: 1 week

E4. Patients with known additional that is progressing or has required active treatment within the past 3 years.

Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin on a location other than the vulva, or carcinoma in situ (e.g. of the breast, cervix or bladder) that have undergone potentially curative therapy are not excluded.

E5. Known allergy or to any of the study drugs or any of the study drug .

E6. Patients with evidence of significant uncontrolled infection or concomitant disease, or psychiatric illness/social situations that could affect compliance with the protocol or interpretation of results.

E7. Patients with prior organ or bone marrow transplant.

E8. Patients with known active , C, or infection or any active infection requiring systemic therapy.

E9. Patients with known or suspected active disease. Note: Patients with skin disorders (such as vitiligo, psoriasis or alopecia), type I diabetes mellitus, hypothyroidism only requiring hormone replacement or conditions not expected to recur in the absence of an external trigger are eligible.

E10. Pregnant or breastfeeding women.

Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Adult female patient with VSCC

    Patients must have histologically confirmed diagnosis of vulvar squamous cell carcinoma (VSCC).

    Drug: Imiquimod 5% cream · Drug: Nivolumab

Interventions

  • DrugImiquimodStudies of ImiquimodImiquimod pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    At the starting dose (DL1) : 5 consecutive days per week for 4 weeks At DL-1: 3 consecutive days per week for 4 weeks

  • At DL1 and DL-1: Administration IV at a dose of 40 mg, every two weeks for 6 weeks (3 doses)

06

What researchers measure

Primary outcomes

  1. Phase I Safety run-in: Dose-limiting toxicity (DLT) related to imiquimod and/or nivolumab, occurring during the induction period (first 6 weeks of treatment)

    Dose-limiting toxicity (DLT) defined as any adverse event (AE) related to imiquimod and/or nivolumab, occurring during the induction period (first 6 weeks of treatment, i.e., DLT period) and graded according to the NCI-CTCAE V6.0 classification: * Grade 4 non-laboratory AE including skin toxicity; * Grade 3 non-laboratory AE lasting \>14 days despite optimal supportive care with the following exceptions: Influenza-like symptoms and application site reaction related to imiquimod * Any grade 3 or grade 4 laboratory value with clinical symptoms requiring medical intervention or hospitalization, and persisting for more than 14 days; * Any imiquimod site application AE or nivolumab related AE postponing the surgery of at least 14 days * Any other AE evaluated as clinically significant by investigator and sponsor, for instance delaying the nivolumab administration for more than 14 days * Any toxic death, grade 5 AE

    Time frame: From Cycle 1 Day 1 to week 6

  2. Phase II: To evaluate the clinical efficacy of imiquimod and nivolumab combination in adult patients with resectable primary VSCC

    Clinical ORR (objective response rate) as per RECIST 1.1 category documented by calipers using standardized digital photography with reference ruler at the time of surgery

    Time frame: From Cycle 1 Day 1 to surgery (up to 3 cycles - each cycle is 14 days)

Secondary outcomes

  1. Evaluation of the Pathological Response

    The pathological tumor response (pTR) is defined as the presence of tumor cell necrosis and keratinous debris with giant cell/histiocytic reaction, quantified as a percentage of the overall tumor bed (area pathologic response/area pathologic response plus viable tumor): pTR-0 (\<10%), pTR-1 (10%-49%), pTR-2 (≥50%), pTR-3 (100%, complete response). The pTR will be quantified in increments of 10%.

    Time frame: At time of surgery

  2. Rate of positive margin

    Rate of patients with positive margin defined as \<8mm

    Time frame: At time of surgery

  3. Rate of positive Sentinel Lymph Node

    Rate of patients with positive Sentinel Lymph Node (SLN)

    Time frame: Through study completion, up to 3 years

  4. Rate of patients undergoing RT

    Rate of patients undergoing radiotherapy

    Time frame: Through study completion, up to 3 years

  5. Evaluation of Overall Survival (OS)

    Overall survival defined as the time between treatment initiation (C1D1) and death from any cause. Patients still alive at the time of analysis will be censored at the date of last news they are known to be alive.

    Time frame: From Cycle 1 Day 1 to the date of death from any cause (assessed up to 3 years)

  6. Recurrence Free Survival (RFS)

    Recurrence Free Survival (RFS): defined as the time from C1D1 to the first documented disease recurrence or death from any cause, whichever occurs first. Patients who are alive and without evidence of recurrence at the time of analysis will be censored at the date of their last disease assessment.

    Time frame: From Cycle 1 Day 1 to the date of first documented disease recurrence or death (assessed up to 3 years)

  7. Evaluation of surgical complications

    The frequency of surgical complications: * The percentage of wound breakdown (dehiscence) in the vulva defined as larger than one third of the length of excision. * The percentage of wound breakdown (dehiscence) in the groins defined as larger than one third of the length of excision. * The percentage of wound infection in the vulva defined as a clinical infection (e.g. the presence of a purulent exudate and/or a positive culture with the presence of erythema, oedema, and localized pain involving skin and subcutaneous tissue) which requires antibiotic therapy * The percentage of wound infection in the groins defined as a clinical infection (e.g. the presence of a purulent exudate and/or a positive culture with the presence of erythema, oedema, and localized pain involving skin and subcutaneous tissue) which requires antibiotic therapy. * The percentage of patients with lymphocyst formation defined by greater than 4 cm in diameter and confirmed by puncture or ultrasound

    Time frame: From surgery to short term safety visit (occuring 30 days after surgery)

  8. To assess the impact of the proposed induction treatment on patient QoL

    To assess the impact of the proposed induction treatment on patient QoL with Quality of Life questionnaires: * EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30): scores range from 0 to 100, with higher scores indicating better functioning/global health status but worse symptoms * EORTC QLQ-VU34 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Vulva Cancer module with 34 questions): scores range from 0 to 100, with higher scores indicating better functioning/global health status but worse symptoms

    Time frame: From enrollment to Short Term Safety Visit (STSV) (assesed up to 30 days following surgery)

  9. To define the tolerability of the proposed therapeutic strategy

    Incidence and severity of AE according to NCI CTCAE V6.0

    Time frame: Through study completion, up to 3 years

Other outcomes

  1. To study the impact of the treatment on the Tumour Microenvironment (TME) immune profile : Changes in CD8 infiltrate

    Exploratory analyses in pretreatment tumour biopsies versus surgical specimen will be performed in an effort to understand the impact of the treatment by nivolumab and imiquimod combination on the Tumor Microenvironment (TME) immune profile. Exploratory data will be summarized using descriptive statistics (e.g. N, medians, inter-quartile range, and mean, standard deviation, minimum and maximum for continuous variables and frequency counts and percentages for categorical variables). The relationship between TME immune profile and efficacy variables will be assessed using appropriate multivariate models. The exploratory analyses will include the following : changes in CD8 infiltrate

    Time frame: Through study completion, up to 3 years

  2. To study the impact of the treatment on the Tumour Microenvironment (TME) immune profile: CD8/FOXP3 ratio

    Exploratory analyses in pretreatment tumour biopsies versus surgical specimen will be performed in an effort to understand the impact of the treatment by nivolumab and imiquimod combination on the Tumor Microenvironment (TME) immune profile. Exploratory data will be summarized using descriptive statistics (e.g. N, medians, inter-quartile range, and mean, standard deviation, minimum and maximum for continuous variables and frequency counts and percentages for categorical variables). The relationship between TME immune profile and efficacy variables will be assessed using appropriate multivariate models. The exploratory analyses will include the following : CD8/FOXP3 ratio

    Time frame: Through study completion, up to 3 years

  3. To study the impact of the treatment on the Tumour Microenvironment (TME) immune profile : T effector memory cells

    Exploratory analyses in pretreatment tumour biopsies versus surgical specimen will be performed in an effort to understand the impact of the treatment by nivolumab and imiquimod combination on the Tumor Microenvironment (TME) immune profile. Exploratory data will be summarized using descriptive statistics (e.g. N, medians, inter-quartile range, and mean, standard deviation, minimum and maximum for continuous variables and frequency counts and percentages for categorical variables). The relationship between TME immune profile and efficacy variables will be assessed using appropriate multivariate models. The exploratory analyses will include the following : T effector memory cells functional analysis (cytokine production of interferon gamma)

    Time frame: Through study completion, up to 3 years

  4. To study the impact of the treatment on the Tumour Microenvironment (TME) immune profile: immune checkpoints expression (PD-1, TIGIT, TIM3, CTLA4, CD39)

    Exploratory analyses in pretreatment tumour biopsies versus surgical specimen will be performed in an effort to understand the impact of the treatment by nivolumab and imiquimod combination on the Tumor Microenvironment (TME) immune profile. Exploratory data will be summarized using descriptive statistics (e.g. N, medians, inter-quartile range, and mean, standard deviation, minimum and maximum for continuous variables and frequency counts and percentages for categorical variables). The relationship between TME immune profile and efficacy variables will be assessed using appropriate multivariate models. The exploratory analyses will include the following : immune checkpoints expression (PD-1, TIGIT, TIM3, CTLA4, CD39)

    Time frame: Through study completion, up to 3 years

  5. To identify biomarkers as predictive factors of efficacy

    Exploratory analyses to identify biomarkers as predictive factors of efficacy will be performed. Exploratory data will be summarized using descriptive statistics (e.g. N, medians, inter-quartile range, and mean, standard deviation, minimum and maximum for continuous variables and frequency counts and percentages for categorical variables). The relationship between biomarker and efficacy variables will be assessed using appropriate multivariate models. The biomarkers analyzed will include the following : * HPV dependent vs HPV independent VSCC (p16 IHC status) * TP53 mutation * TME immune profile * PD-L1 expression

    Time frame: Through study completion, up to 3 years

07

Study locations

11 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jul 1, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added
Show 8 added (8 France)
  • CH de Bourg-en-Bresse · Bourg-en-Bresse, France
  • Centre Jean Perrin · Clermont-Ferrand, France
  • CHU Clermont-Ferrand · Clermont-Ferrand, France
  • Centre Oscar Lambret · Lille, France
  • HCL - Centre Hospitalier Lyon Sud · Lyon, France
  • Hôpital Privé Jean Mermoz · Lyon, France
  • Institut Paoli-Calmettes · Marseille, France
  • IUCT Oncopole Claudius Regaud · Toulouse, France
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    8 sites added
    Show 8 added (8 France)
    • CH de Bourg-en-Bresse · Bourg-en-Bresse, France
    • Centre Jean Perrin · Clermont-Ferrand, France
    • CHU Clermont-Ferrand · Clermont-Ferrand, France
    • Centre Oscar Lambret · Lille, France
    • HCL - Centre Hospitalier Lyon Sud · Lyon, France
    • Hôpital Privé Jean Mermoz · Lyon, France
    • Institut Paoli-Calmettes · Marseille, France
    • IUCT Oncopole Claudius Regaud · Toulouse, France

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07679841
Lead sponsor
Centre Leon Berard
Responsible party
Sponsor
First posted
Jul 1, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Sep 30, 2026

Study contacts

Olivia LE SAUX, MD, PhD
Contact
olivia.lesaux@lyon.unicancer.fr
+33469856483

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Imiquimod · Nivolumab

Start the discussion